Cell therapy for difficult-to-treat myasthenia gravis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This early study tests a new cell therapy (GC012F) for people with difficult-to-treat generalized myasthenia gravis. The treatment aims to reset the immune system to reduce muscle weakness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Are 18 to 75 years old.
- Have generalized myasthenia gravis that hasn't improved with standard treatments.
- Score at least 11 on a muscle strength test and have daily symptoms score of 6 or more.
- Test positive for AChR or MuSK antibodies.
- Be willing to practice effective birth control during the study and for 1 year after.
- Have no active infections or serious heart, kidney, or liver problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called GC012F for people with generalized myasthenia gravis (gMG) that hasn't improved with standard treatments. The goal is to see if it can reduce symptoms and improve daily life.
This trial tests a new cell therapy called CABA-201 for people with generalized myasthenia gravis. It aims to reset the immune system to reduce muscle weakness and improve daily functioning.
This trial tests an experimental drug (EA5) injected under the skin or into a vein for people with a specific form of myasthenia gravis (caused by AChR antibodies). The goal is to find the safest dose and see how well it may reduce muscle weakness.
This trial tests an experimental therapy using special immune cells (UCAR T-cells) to target and destroy certain B cells that produce the antibodies causing myasthenia gravis. It's for people whose symptoms are not well controlled by standard treatments and may offer a new option.
This trial tests a new immune cell treatment (CAR T-cells) for people with generalized myasthenia gravis that has not improved with standard treatments. It aims to reduce symptoms by targeting and calming the immune system's attack on muscles.
This trial tests a new cell therapy called anitocabtagene autoleucel (anito-cel) for people with generalized myasthenia gravis (gMG) that is not well controlled with current treatments. The goal is to see if it can reduce symptoms and improve quality of life.
Hear when a new Generalized Myasthenia Gravis (gMG) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.